MSH6 inactivation and emergent temozolomide resistance in human glioblastomas

Clin Neurosurg. 2008:55:165-71.

Authors

Daniel P Cahill¹, Patrick J Codd, Tracy T Batchelor, William T Curry, David N Louis

Affiliation

¹ Neurosurgical Service, Massachusetts General Hospital, Harvard Medical School, Boston, USA.

PMID: 19248684

No abstract available

Publication types

Case Reports

MeSH terms

Antineoplastic Agents, Alkylating / adverse effects
Antineoplastic Agents, Alkylating / therapeutic use*
Brain Neoplasms / drug therapy*
Brain Neoplasms / genetics*
Brain Neoplasms / radiotherapy
Brain Neoplasms / surgery
Chemotherapy, Adjuvant
DNA Mismatch Repair / genetics
DNA Mutational Analysis
DNA-Binding Proteins / genetics*
Dacarbazine / adverse effects
Dacarbazine / analogs & derivatives*
Dacarbazine / therapeutic use
Disease Progression
Drug Resistance, Neoplasm / genetics*
Female
Gene Silencing*
Glioblastoma / drug therapy*
Glioblastoma / genetics*
Glioblastoma / radiotherapy
Glioblastoma / surgery
Humans
Middle Aged
Neoplasm Recurrence, Local / diagnosis
Neoplasm Recurrence, Local / drug therapy
Neoplasm Recurrence, Local / genetics
Radiotherapy, Adjuvant
Temozolomide

Substances

Antineoplastic Agents, Alkylating
DNA-Binding Proteins
G-T mismatch-binding protein
Dacarbazine
Temozolomide